Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;63(1):33-40.
doi: 10.1016/j.antiviral.2004.02.003.

Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir

Affiliations

Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir

Debra C Quenelle et al. Antiviral Res. 2004 Jul.

Abstract

Orthopoxviruses, including smallpox, monkeypox and molluscipox, pose risks to human health through bioterrorist acts or natural transmission. There is no approved therapy for orthopoxvirus infections; however, cidofovir (CDV) has been approved as an investigational new drug for emergency treatment of adverse effects following smallpox vaccination. For evaluation of new therapies directed against orthopoxvirus infections, we have utilized immunocompetent, hairless mice (SKH-1) inoculated by a cutaneous route with cowpox virus (CV) or vaccinia virus (VV). Mice subsequently developed skin lesions and virus was recovered from the site of inoculation and quantified. Skin biopsies were evaluated microscopically, revealing brick-like eosinophilic, intracytoplasmic inclusion bodies characteristic of orthopoxvirus infection. SKH-1 mice fully recovered from either CV or VV infection. Immunodeficient Athymic or Rhino mice inoculated with CV or VV had more lesions and severe disease than SKH-1 mice. CV-infected SKH-1 mice were treated either with systemic or topical CDV. Although some protection was achieved with systemic treatment, 5% topical CDV was most effective at reducing virus titers in skin, lung, kidney, and spleen. These models may provide a means for evaluating efficacy of new therapies directed against orthopoxvirus diseases and further confirm the topical activity of CDV against cutaneous infections.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Orofacial area of SKH-1 mouse. White arrow indicates site of inoculation. Yellow arrow indicates general location of facial skin lesions. (B) Rash-like lesions on infected SKH-1 mouse. (C) Vesicular lesions on lateral thorax. (D) Histopathology of biopsy of vesicular lesion from CV-infected SKH-1 mouse 6 days post-viral inoculation.
Fig. 2
Fig. 2
Alteration of VV–WR virus titers in organs of SKH-1 mice treated topically three times daily with 5% CDV or i.p. once daily with 50 mg/kg CDV beginning at 24 h after infection and continued through day 7.

Similar articles

Cited by

References

    1. Bienvenu B, Martinez F, Devergie A, Rybojad M, Rivet J, Bellenger P, Morel P, Gluckman E, Lebbe C. Topical use of cidofovir induced acute renal failure. Transplantation. 2002;73:661–662. - PubMed
    1. Boyle J.J, Haff R.F, Stewart R.C. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother. 1967;6:536–539. - PubMed
    1. Bray M, Martinez M, Smee D.F, Kefauver D, Thompson E, Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000;181:10–19. - PubMed
    1. Buller R.M.L. The BALB/c mouse as a model to study orthopoxviruses. Curr. Top. Microbiol. Immunol. 1985;122:148–153. - PubMed
    1. Centers for Disease Control and Prevention, 2003a. Multistate outbreak of monkeypox—Illinois, Indiana, and Wisconsin, 2003. MMWR Morb. Mortal. Wkly. Rep. 52, 537–540. - PubMed

Publication types

MeSH terms